{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:45:05Z","timestamp":1793832305891,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]},{"name":"Fresenius Medical Care GmbH, Bad Homburg, Germany","award":["n.a."],"award-info":[{"award-number":["n.a."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Regional citrate anticoagulation (RCA) for continuous renal replacement therapy is widely used in intensive care units (ICUs). However, concern exists about the safety of citrate in patients with liver failure (LF). The aim of this study was to evaluate safety and efficacy of RCA in ICU patients with varying degrees of impaired liver function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a multicenter, prospective, observational study, 133 patients who were treated with RCA and continuous venovenous hemodialysis (RCA-CVVHD) were included. Endpoints for safety were severe acidosis or alkalosis (pH \u22647.2 or \u22657.55, respectively) and severe hypo- or hypercalcemia (ionized calcium \u22640.9 or \u22651.5\u00a0mmol\/L, respectively) of any cause. The endpoint for efficacy was filter lifetime. For analysis, patients were stratified into three predefined liver function or LF groups according to their baseline serum bilirubin level (normal liver function \u22642\u00a0mg\/dl, mild LF &gt;2 to \u22647\u00a0mg\/dl, severe LF &gt;7\u00a0mg\/dl).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 48 patients with normal liver function, 43 with mild LF, and 42 with severe LF. LF was predominantly due to ischemia (39\u00a0%) or multiple organ dysfunction syndrome (27\u00a0%). The frequency of safety endpoints in the three patient strata did not differ: severe alkalosis (normal liver function 2\u00a0%, mild LF 0\u00a0%, severe LF 5\u00a0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.41), severe acidosis (normal liver function 13\u00a0%, mild LF 16\u00a0%, severe LF 14\u00a0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.95), severe hypocalcemia (normal liver function 8\u00a0%, mild LF 14\u00a0%, severe LF 12\u00a0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.70), and severe hypercalcemia (0\u00a0% in all strata). Only three patients showed signs of impaired citrate metabolism. Overall filter patency was 49\u00a0% at 72\u00a0h. After censoring for stop of the treatment due to non-clotting causes, estimated 72-h filter survival was 96\u00a0%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RCA-CVVHD can be safely used in patients with LF. The technique yields excellent filter patency and thus can be recommended as first-line anticoagulation for the majority of ICU patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ISRCTN Registry identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN92716512\">ISRCTN92716512<\/jats:ext-link>\n                      . Date assigned: 4 December 2008.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-015-1066-7","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T19:10:39Z","timestamp":1443467439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1446-0943","authenticated-orcid":false,"given":"Torsten","family":"Slowinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Morgera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Joannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Henneberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Helset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsti","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kozik-Jaromin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hasslacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-H.","family":"Neumayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Kindgen-Milles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1\u2013138.","journal-title":"Kidney Int Suppl"},{"key":"1066_CR2","first-page":"602","volume":"20","author":"MG Betjes","year":"2007","unstructured":"Betjes MG, van Oosterom D, van Agteren M, van de Wetering J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol. 2007;20:602\u20138.","journal-title":"J Nephrol."},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/ndt\/gfq575","volume":"26","author":"GR Hetzel","year":"2011","unstructured":"Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant. 2011;26:232\u20139.","journal-title":"Nephrol Dial Transplant."},{"key":"1066_CR4","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1111\/j.1523-1755.2005.00342.x","volume":"67","author":"DJ Kutsogiannis","year":"2005","unstructured":"Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005;67:2361\u20137.","journal-title":"Kidney Int."},{"key":"1066_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00134-003-2047-x","volume":"30","author":"M Monchi","year":"2004","unstructured":"Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260\u20135.","journal-title":"Intensive Care Med"},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/CCM.0b013e3181a00a92","volume":"37","author":"S Morgera","year":"2009","unstructured":"Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid\u2013base status. Crit Care Med. 2009;37:2018\u201324.","journal-title":"Crit Care Med."},{"key":"1066_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/CCM.0b013e3181953c5e","volume":"37","author":"HM Oudemans-van Straaten","year":"2009","unstructured":"Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37:545\u201352.","journal-title":"Crit Care Med."},{"key":"1066_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/cc5937","volume":"11","author":"M Joannidis","year":"2007","unstructured":"Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care. 2007;11:218.","journal-title":"Crit Care."},{"key":"1066_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1042\/bj1140215","volume":"114","author":"DG Nicholls","year":"1969","unstructured":"Nicholls DG, Garland PB. The control of isocitrate oxidation by rat liver mitochondria. Biochem J. 1969;114:215\u201325.","journal-title":"Biochem J."},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/039139880803100414","volume":"31","author":"D Kindgen-Milles","year":"2008","unstructured":"Kindgen-Milles D, Amman J, Kleinekofort W, Morgera S. Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation. Int J Artif Organs. 2008;31:363\u20136.","journal-title":"Int J Artif Organs."},{"key":"1066_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/00003246-200104000-00010","volume":"29","author":"HU Meier-Kriesche","year":"2001","unstructured":"Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med. 2001;29:748\u201352.","journal-title":"Crit Care Med."},{"key":"1066_CR12","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1097\/01.CCM.0000084871.76568.E6","volume":"31","author":"L Kramer","year":"2003","unstructured":"Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31:2450\u20135.","journal-title":"Crit Care Med."},{"key":"1066_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2010.01.042","volume":"53","author":"T Lisman","year":"2010","unstructured":"Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol. 2010;53:362\u201371.","journal-title":"J Hepatol."},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jhep.2009.05.028","volume":"51","author":"B Agarwal","year":"2009","unstructured":"Agarwal B, Shaw S, Hari MS, Burroughs AK, Davenport A. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different? J Hepatol. 2009;51:504\u20139.","journal-title":"J Hepatol."},{"key":"1066_CR15","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1186\/cc11485","volume":"16","author":"C Schultheiss","year":"2012","unstructured":"Schultheiss C, Saugel B, Phillip V, Thies P, Noe S, Mayr U, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012;16:R162.","journal-title":"Crit Care."},{"key":"1066_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/CCM.0b013e3181fee8a4","volume":"39","author":"P Faybik","year":"2011","unstructured":"Faybik P, Hetz H, Mitterer G, Krenn CG, Schiefer J, Funk GC, et al. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med. 2011;39:273\u20139.","journal-title":"Crit Care Med."},{"key":"1066_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/039139880302600403","volume":"26","author":"H Morimatsu","year":"2003","unstructured":"Morimatsu H, Uchino S, Bellomo R, Ronco C. Continuous renal replacement therapy: does technique influence electrolyte and bicarbonate control? Int J Artif Organs. 2003;26:289\u201396.","journal-title":"Int J Artif Organs."},{"key":"1066_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0272-6386(01)80116-5","volume":"37","author":"JR Zivin","year":"2001","unstructured":"Zivin JR, Gooley T, Zager RA, Ryan MJ. Hypocalcemia: a pervasive metabolic abnormality in the critically ill. Am J Kidney Dis. 2001;37:689\u201398.","journal-title":"Am J Kidney Dis."},{"key":"1066_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0002-9343(88)90415-9","volume":"84","author":"TK Desai","year":"1988","unstructured":"Desai TK, Carlson RW, Geheb MA. Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting. Am J Med. 1988;84:209\u201314.","journal-title":"Am J Med."},{"key":"1066_CR20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/MAT.0b013e31817dc3be","volume":"54","author":"D Kindgen-Milles","year":"2008","unstructured":"Kindgen-Milles D, Kram R, Kleinekofort W, Morgera S. Treatment of severe hypercalcemia using continuous renal replacement therapy with regional citrate anticoagulation. ASAIO J. 2008;54:442\u20134.","journal-title":"ASAIO J."},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1042\/bj1140589","volume":"114","author":"T K\u00f6nig","year":"1969","unstructured":"K\u00f6nig T, Nicholls DG, Garland PB. The inhibition of pyruvate and l\ns(+)-isocitrate oxidation by succinate oxidation in rat liver mitochondria. Biochem J. 1969;114:589\u201396.","journal-title":"Biochem J."},{"key":"1066_CR22","first-page":"360","volume":"116","author":"D Gong","year":"2003","unstructured":"Gong D, Ji D, Xu B, Xie H, Liu Y, Li L. Regional citrate anticoagulation in critically ill patients during continuous blood purification. Chin Med J (Engl). 2003;116:360\u20133.","journal-title":"Chin Med J (Engl)"},{"key":"1066_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1042\/bj0900225","volume":"90","author":"JB Chappell","year":"1964","unstructured":"Chappell JB. The oxidation of citrate, isocitrate and cis-aconitate by isolated mitochondria. Biochem J. 1964;90:225\u201337.","journal-title":"Biochem J."},{"key":"1066_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcrc.2013.10.015","volume":"29","author":"D Khadzhynov","year":"2014","unstructured":"Khadzhynov D, Schelter C, Lieker I, Mika A, Staeck O, Neumayer HH, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care. 2014;29:265\u201371.","journal-title":"J Crit Care."},{"key":"1066_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/0041-008X(88)90040-3","volume":"93","author":"LL Meyers","year":"1988","unstructured":"Meyers LL, Beierschmitt WP, Khairallah EA, Cohen SD. Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol Appl Pharmacol. 1988;93:378\u201387.","journal-title":"Toxicol Appl Pharmacol."},{"key":"1066_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/0003-9861(89)90504-3","volume":"273","author":"RR Ramsay","year":"1989","unstructured":"Ramsay RR, Rashed MS, Nelson SD. In vitro effects of acetaminophen metabolites and analogs on the respiration of mouse liver mitochondria. Arch Biochem Biophys. 1989;273:449\u201357.","journal-title":"Arch Biochem Biophys."},{"key":"1066_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.jvca.2004.07.016","volume":"18","author":"MF James","year":"2004","unstructured":"James MF, Roche AM. Dose\u2013response relationship between plasma ionized calcium concentration and thrombelastography. J Cardiothorac Vasc Anesth. 2004;18:581\u20136.","journal-title":"J Cardiothorac Vasc Anesth."},{"key":"1066_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000046075","volume":"89","author":"A Calatzis","year":"2001","unstructured":"Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H. Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron. 2001;89:233\u20136.","journal-title":"Nephron."},{"key":"1066_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1089-3261(03)00134-X","volume":"8","author":"RH Moseley","year":"2004","unstructured":"Moseley RH. Sepsis and cholestasis. Clin Liver Dis. 2004;8:83\u201394.","journal-title":"Clin Liver Dis."},{"key":"1066_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0016-5085(89)90081-4","volume":"97","author":"JG O\u2019Grady","year":"1989","unstructured":"O\u2019Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439\u201345.","journal-title":"Gastroenterology."},{"key":"1066_CR31","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1093\/ndt\/gfp017","volume":"24","author":"J Kozik-Jaromin","year":"2009","unstructured":"Kozik-Jaromin J, Nier V, Heemann U, Kreymann B, B\u00f6hler J. Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol Dial Transplant. 2009;24:2244\u201351.","journal-title":"Nephrol Dial Transplant."}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-015-1066-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-015-1066-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-015-1066-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-015-1066-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T06:01:07Z","timestamp":1627884067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-015-1066-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1186\/s13054-015-1066-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"29 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"349"}}